Deepull Secures €50 Million in Series C Funding with Cuatrecasas' Guidance

Cuatrecasas, a prestigious law firm, has successfully advised Deepull Diagnostics in securing a €50 million Series C investment round. Deepull, known for its innovative medical diagnostic solutions, will leverage this funding to complete clinical validations and advance the regulatory approval process for its UllCORE system. The system, which has been recognized by the U.S. FDA as a Breakthrough Device, provides a fully automated diagnostic process, offering rapid results for a wide array of pathogens causing sepsis. This funding round represents a significant milestone for Deepull as it positions the company towards delivering transformative healthcare solutions globally. The success of the investment round underscores the vitality of the life sciences sector in the region, highlighted by Elena Cuatrecasas, who led the legal advisory effort.